Sellas Life Sciences Group Inc Total Liabilities
Sellas Life Sciences Group Inc total liabilities. Based on the latest financial reports, Sellas Life Sciences Group Inc (SLS) has total liabilities worth $7.73 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Sellas Life Sciences Group Inc (SLS) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Sellas Life Sciences Group Inc (2007–2025)
Total liabilities of Sellas Life Sciences Group Inc from 2007 to 2025. This chart illustrates how Sellas Life Sciences Group Inc's total liabilities have evolved over time, based on quarterly financial data. Check Sellas Life Sciences Group Inc (SLS) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Sellas Life Sciences Group Inc Competitors by Total Liabilities
The table below lists competitors of Sellas Life Sciences Group Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Henan Yuneng Holdings Co Ltd
SHE:001896
|
China | CN¥28.64 Billion |
|
Centrus Energy Corp.
NYSE MKT:LEU
|
USA | $1.68 Billion |
|
Cyfrowy Polsat SA
WAR:CPS
|
Poland | zł20.27 Billion |
|
Westshore Terminals Investment Corp
TO:WTE
|
Canada | CA$1.58 Billion |
|
Evergreen Aviation Tech Corp
TW:2645
|
Taiwan | NT$11.99 Billion |
|
Minerals Technologies Inc
NYSE:MTX
|
USA | $1.92 Billion |
|
Whirlpool Corporation
NYSE:WHR
|
USA | $13.40 Billion |
|
Chang Wah Technology Co Ltd
TWO:6548
|
Taiwan | NT$13.17 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Sellas Life Sciences Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Sellas Life Sciences Group Inc total assets.
Liquidity & Leverage Metrics
Sellas Life Sciences Group Inc Total Liabilities Ratios Explained
Sellas Life Sciences Group Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sellas Life Sciences Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sellas Life Sciences Group Inc (2007–2025)
The table below shows the annual total liabilities of Sellas Life Sciences Group Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.47 Million | -25.01% |
| 2024-12-31 | $9.97 Million | -29.79% |
| 2023-12-31 | $14.20 Million | -11.79% |
| 2022-12-31 | $16.09 Million | +164.67% |
| 2021-12-31 | $6.08 Million | -66.39% |
| 2020-12-31 | $18.09 Million | +72.00% |
| 2019-12-31 | $10.52 Million | -9.89% |
| 2018-12-31 | $11.67 Million | -62.90% |
| 2017-12-31 | $31.46 Million | -15.34% |
| 2016-12-31 | $37.15 Million | -45.86% |
| 2015-12-31 | $68.63 Million | +58.03% |
| 2014-12-31 | $43.43 Million | -47.10% |
| 2013-12-31 | $82.09 Million | +201.47% |
| 2012-12-31 | $27.23 Million | +30.56% |
| 2011-12-31 | $20.86 Million | +313.32% |
| 2010-12-31 | $5.05 Million | -8.44% |
| 2009-12-31 | $5.51 Million | +296.19% |
| 2008-12-31 | $1.39 Million | +5.06% |
| 2007-12-31 | $1.32 Million | -- |
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or … Read more